Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
KMT2A-MLLT10 is one of the common chimeric genes diagnosed in acute leukemia with KMT2A rearrangement (8%), especially in acute myeloid leukemia (AML; 18%).
|
30624859 |
2019 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although it is presently unclear whether these sarcomas belong to a single group, the well-established role of KMT2A fusions as drivers of acute leukaemia and a recent publication regarding identification of YAP1-KMT2A in one unclassifiable sarcoma support the significance of these fusions.
|
31136005 |
2019 |
Acute leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SETD2, an epigenetic tumor suppressor, is frequently mutated in MLL-rearranged (MLLr) leukemia and relapsed acute leukemia (AL).
|
30967619 |
2019 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overlap of MLL bcr sequences associated with both infant acute leukemia and therapy-related leukemia following exposure to the topoisomerase II inhibitor etoposide led to the hypothesis that exposure during pregnancy to biochemically similar compounds may promote infant acute leukemia.
|
30387535 |
2019 |
Acute leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
|
30707474 |
2019 |
Acute leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed at assessing if the cell-of-origin of t(4;11) MLL-AF4 acute leukemia is sensitive to a viral or bacterial mimic and if maternal immune activation can lead to a full-blown leukemia.
|
31381950 |
2019 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mixed lineage leukemia 1 (MLL1), an important member of histone methyltransferases (HMT) family, is closely associated with human acute leukemia.
|
31132972 |
2019 |
Acute leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chromosomal rearrangements involving the mixed-lineage leukemia (MLL1) gene are common in a unique group of acute leukemias, with more than 100 fusion partners in this malignancy alone.
|
30548174 |
2019 |
Acute leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Acute leukemias (AL) with a Mixed Lineage Leukemia (MLL) gene rearrangement (MLLr) represent a group of leukemic entities conferring intermediate to adverse prognoses.
|
30446944 |
2019 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases.
|
29978456 |
2018 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provides a comprehensive analysis of the MLL recombinome in acute leukemia and demonstrates that the establishment of patient-specific chromosomal fusion sites allows the design of specific PCR primers for minimal residual disease analyses for all patients.
|
28701730 |
2018 |
Acute leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, compounds 1, 23 and 44 were chosen to evaluate for their antiproliferative activities on the MLL-AF4-expression acute leukemia cell line (MV4-11), other cancer cell lines (MDA-MB-231, A549, 22Rv1) and the non-cancer cell lines (HUV-EC-C, MRC5, RPTEC).
|
29730189 |
2018 |
Acute leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The breakpoint cluster region of the MLL gene (MLLbcr) is frequently rearranged in therapy-related and infant acute leukaemia, but the destabilizing mechanism is poorly understood.
|
28626219 |
2018 |
Acute leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Activating signaling mutations are common in acute leukemia with KMT2A (previously MLL) rearrangements (KMT2A-R).
|
29720585 |
2018 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that one of the ENL YEATS-selective inhibitors, XL-13m, engages with endogenous ENL, perturbs the recruitment of ENL onto chromatin, and synergizes the BET and DOT1L inhibition-induced downregulation of oncogenes in MLL-rearranged acute leukemia.
|
30374167 |
2018 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
MLL gene is involved in more than 80 known genetic fusions in acute leukemia.
|
29384595 |
2018 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The protein-protein interaction between menin and mixed-lineage leukemia 1 (MLL1) plays an important role in development of acute leukemia with translocations of the MLL1 gene and in solid tumors.
|
29738674 |
2018 |
Acute leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
By contrast, MLL-translocations in acute leukemia patients are hard to treat, display a high relapse rate and the overall survival rate is still very poor.
|
28943239 |
2018 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chromosomal rearrangements of the mixed lineage leukemia (MLL/KMT2A) gene leading to oncogenic MLL-fusion proteins occur in ~10% of acute leukemias and are associated with poor clinical outcomes, emphasizing the need for new treatment modalities.
|
27840424 |
2017 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mixed-lineage leukemia 1 (MLL1) gene (now renamed <i>Lysine [K]-specific MethylTransferase 2A</i> or <i>KMT2A</i>) on chromosome 11q23 is disrupted in a unique group of acute leukemias.
|
28232907 |
2017 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, using unbiased CRISPR-Cas9 technology to perform a genome-scale loss-of-function screen in an MLL-AF4-positive acute leukaemia cell line, we identify ENL as an unrecognized gene that is specifically required for proliferation in vitro and in vivo.
|
28241139 |
2017 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in <i>SETD2</i><i>,</i> encoding the histone 3 lysine 36 trimethyltransferase, are enriched in relapsed acute lymphoblastic leukemia and MLL-rearranged acute leukemia.
|
29018079 |
2017 |
Acute leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PTPN11 mutation, a RAS signaling pathway mutation, is associated with MLL translocations in acute leukemia.
|
27859216 |
2017 |
Acute leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The hallmark of the AOP is the formation of MLL gene rearrangements via topo II poisoning, leading to fusion genes and ultimately acute leukaemia by global (epi)genetic dysregulation.
|
28536863 |
2017 |
Acute leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Its chromatin-tethering ability is linked to at least two unrelated diseases-HIV infection and MLL-rearranged acute leukemia.
|
27290878 |
2016 |